Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Phenomenex to Present Four Workshops at Pittcon 2013

Published: Monday, December 17, 2012
Last Updated: Monday, December 17, 2012
Bookmark and Share
Workshops will cover proteins, environmental contaminants, oligonucleotide therapeutics and core-shell technology.

“Survey of Recent Advances in Protein Analysis” will be presented on Monday, March 18 at 8:00 a.m. in Room 1268. Speakers include industry experts from Amgen, Genentech, AB SCIEX and Phenomenex. Panelists will discuss current challenges and assay requirements as well as how they are integrating new technologies in chromatography and mass spectrometry for faster and more accurate protein analysis.

“Emerging Environmental Contaminants:  Methodologies and Practices for Meeting New Performance Requirements” will be presented on Wednesday, March 20 at 8:00 a.m. in Room 1680. Scheduled panelists are from the EPA, TestAmerica, Horizon Technology, Phenova Certified Reference Materials and Phenomenex. Topics will include new testing requirements as well as information on how to achieve the highest efficiencies plus insight on the latest instrumentation in LC/MS/MS, automated sample preparation and GC/HRMS. This workshop will also cover proficiency testing and ways to optimize methods to maintain accreditation.

“New Advances in the Analysis of Oligonucleotide Therapeutics” will be presented on Wednesday, March 20 at 2:00 p.m. in Room 1268. Panelists will include experts from Merck, Novatia, AB SCIEX and Phenomenex. In this workshop, researchers from the growing field of therapeutic product development will discuss new analytical methods as well as increasing demands for the identification and quantitation of low-level genotoxic impurities from biological fluids.

“The Present and Future of Core-Shell Column Technology” will be presented on Thursday, March 21 at 8:00 a.m. in Room 2300. The panel will include experts from The Pennsylvania State University, Abbot Laboratories, Merck, Agilent, Advanced Materials Technology and Phenomenex. In this session industry experts will discuss the benefits they are realizing from using core-shell column technology in their laboratories. The workshop will also cover the latest methods and techniques that enable researchers to get the most from core-shell technology.

Phenomenex, celebrating its 30th anniversary in 2012, is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, government and academic laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Phenomenex Clarity® OTX™ Receives R&D 100 Award for Innovation
Phenomenex has received this award for the fifth consecutive year in 2010 for two of its products.
Monday, July 26, 2010
Phenomenex Announces Acquisition of two Companies in Italy and Denmark
Phenomenex expands its market presence and strengthens brand identity by acquiring customer-focused distributors in chromatography consumables.
Friday, April 13, 2007
Scientific News
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!